1. Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France. (7th February 2023) Authors: Oppe, Mark; Muresan, Bogdan; Chan, Katie; Radu, Xenia; Schultz, Bob G.; Turpin, Robin S.; Nucit, Arnaud; Fenu, Elisabetta Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 23:Number 2(2023) Page Start: 205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗